Anemia risk and mitigation strategies in type 2 diabetic patients: The role of novel antidiabetic agents

doi:10.4239/wjd.v16.i5.105549

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (17)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=15

May 15, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. May 15, 2025; 16(5): 105549
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.105549

Anemia risk and mitigation strategies in type 2 diabetic patients: The role of novel antidiabetic agents

Petra Meliš, Maja Cigrovski Berkovic

Petra Meliš, Department for Endocrinology, Diabetes and Clinical Pharmacology, Clinical Hospital Dubrava, Zagreb 10000, Croatia

Maja Cigrovski Berkovic, Department for Sport and Exercise Medicine, University of Zagreb Faculty of Kinesiology, Zagreb 10000, Croatia

Co-first authors: Petra Meliš and Maja Cigrovski Berkovic.

Author contributions: Meliš P wrote and Cigrovski Berkovic M designed and edited the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Maja Cigrovski Berkovic, MD, PhD, Associate Professor, Department for Sport and Exercise Medicine, University of Zagreb Faculty of Kinesiology, Horvacanski Zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com

Received: January 27, 2025
Revised: March 3, 2025
Accepted: March 24, 2025
Published online: May 15, 2025
Processing time: 89 Days and 13.5 Hours

Core Tip

Core Tip: This review focuses on the overlooked prevalence and effect of anemia in type 2 diabetes, particularly in the context of chronic kidney disease. It focuses on the complicated interplay between anemia, glucose management, and diabetes-related comorbidities, as well as the possibility of emerging antidiabetic medications (sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists) to reduce anemia risk. Furthermore, the study underlines the significance of early identification of anemia and the benefits of newer antidiabetic drugs in terms of cardiovascular and kidney outcomes.